NRAS mutations have also been identified as resistance mechanisms using patient-derived cell line models harboring RET and ROS1 gene fusions, further supporting the idea that cancers often develop resistance using a somewhat finite group of oncogenes following TKI treatment13,21,22. This evidence concerns the gene ROS1 and cancer.